IL-17 inhibitors are specifically associated with higher candidiasis risk compared with other biologics, particularly vs. IL-23 inhibitors (17), and demonstrated superior efficacy in hidradenitis suppurativa (HS) compared with IL-23 inhibitors which showed inconsistent results (18). Here, IL17A is linked to histiocytic sarcoma.